Close Menu

NEW YORK (360Dx) – Finnish diagnostics company Zora Biosciences is working to expand US and European sales of its ceramide lipid-based cardiovascular risk test, CERT.

The company, which specializes in metabolomic-based diagnostics, currently offers the test throughout Finland, as well as in the US through a licensing deal with the Mayo Clinic. It is now working to launch sales in other European countries and is in discussions with other US-based clinical laboratories about licensing agreements for the test, said Reini Hurme, Zora's founder and CEO.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.